Skip to main content

Table 1 Summary baseline characteristics of participants with severe haemophilia A by treatment regimen

From: Assessing the value of bypassing agent therapy used prophylactic versus on-demand, during immune tolerance induction for treatment of inhibitors: a retrospective chart review

Baseline characteristics

Sample size as above unless stated otherwise in the table

BPA treatment type

Total

Statistical significance

Prophylactic (n = 34)

On-demand (n = 13)

n = 47

p-value* (< 0.05)

Gender n (%)

 Male

34 (100)

13 (100)

47 (100)

 

Country, n (%)

 Germany

20 (59)

10 (77)

30 (64)

 

 UK

10 (41)

3 (23)

17 (36)

 

Ethnicity, n (%)

 White

30 (90)

12 (92)

42 (90)

 

 Black

3 (9)

0 (0)

3 (6)

 

 Mixed

1 (1)

1 (8)

2 (4)

 

Age most recent inhibitor (years), mean ± SD

10.6 ± 4.7

10.5 ± 4.1

10.6 ± 4.5

0.952

Family history of an inhibitor, n (%)

n = 33

n = 13

n = 46

 

 Yes

15 (45)

8 (62)

23 (50)

0.326

 No

18 (55)

5 (38)

23 (50)

 

Bleeding events in last 12 months prior to most recent inhibitor, mean ± SD

n = 31

1.9 ± 1.4

n = 13

1.4 ± 1.1

n = 44

1.7 ± 1.2

0.349

Joint bleeding events in last 12 months prior to most recent inhibitor, mean ± SD

n = 31

1.4 ± 1.4

n = 13

1.2 ± 1.0

n = 44

1.3 ± 1.2

0.914

Target joints, n (%)

 Yes

31 (91)

13 (100)

44 (94)

 

 No

3 (9)

0 (0)

3 (6)

0.369

Problem joints, n (%)

 Yes

31 (91)

13 (100)

44 (94)

 

 No

3 (9)

0 (0)

3 (6)

0.369

Frequency of target joints, mean ± SD

6.8 ± 4.3

9.1 ± 3.4

7.4 ± 4.1

0.059

Frequency of problem joints, mean ± SD

6.6 ± 4.3

8.6 ± 3.5

7.2 ± 4.1

0.131

  1. n Sample size; mean Average value; SD Standard deviation; ITI Immune tolerance induction; BPA Bypassing agent
  2. *p-value < 0.05 (statistically significant)